@article{3ab404d8304943dbb22ba655a14e47a3,
title = "CANadian Network and Centre for Trials INternationally (CANNeCTIN): A national network for Canadian-led trials in cardiovascular diseases and diabetes mellitus",
keywords = "Cardiovascular diseases, Clinical research, Diabetes mellitus, Research infrastructure, Research networks",
author = "Cairns, {John A.} and Salim Yusuf and Cook, {Richard J.} and Jafna Cox and Dagenais, {Gilles R.} and Devereaux, {P. J.} and McAlister, {Finlay A.} and Tara McCready",
note = "Funding Information: CANNeCTIN is funded by the CFI ($10 million [M] in capital funding, matched by $15M from other sources and supplemented by $1M in capital maintenance funding from the CFI) and the CIHR ($9.6M in operating funds over five years). The CFI award has been deployed to upgrade and consolidate the operations of the PHRI. As of March 2009, they are located within the David Braley Cardiac, Vascular and Stroke Research Institute, a six-storey building at Hamilton General Hospital in Hamilton that is funded by the CFI awards and other contributions in excess of $90M. The CIHR award provides core support of dedicated staff, enabling a substantial number of pilot studies to be conducted and the personnel infrastructure for multicentre trials, epidemiological studies and national registries to be stabilized. Resources are allocated to support communications, meetings and programs of education and knowledge translation. In addition, the network has raised $200,000 per year for five years in the form of unconditional grants from two companies (AstraZeneca Canada Inc and Boehringer Ingelheim [Canada] Ltd) to initiate pilot studies. Funding Information: The CANadian Network and Centre for Trials INternationally (CANNeCTIN) was jointly funded by the Canadian Institutes of Health Research and the Canadian Foundation for Innovation in April 2008 to provide infrastructure for clinical studies of cardiovascular diseases and diabetes mellitus. Its functional components include a national coordinating centre at the Population Health Research Institute (PHRI) in Hamilton (Ontario), a collaborative Canadian network and an affiliated international network of hospitals and clinics. The rationales for CANNeCTIN include the global health burden of cardiovascular diseases and diabetes, the strengths of randomized controlled trials – particularly large, multicentre and international – and the track record of success of the PHRI. CANNeCTIN will provide investigators from across Canada with opportunities to become the principal investigators of national and international trials coordinated by the PHRI. CANNeCTIN will support priority pilot studies, and successful investigators will be encouraged and assisted to apply for peer review and industrial funding for full studies to be conducted within the network and coordinated by the PHRI. An extensive education program offers hands-on experience in organizing and leading large national/international clinical trials led by accomplished researchers, distance learning courses in clinical research methodology, biostatistics and study coordination, and {\textquoteleft}cutting-edge{\textquoteright} workshops. A knowledge translation program seeks opportunities arising from clinical trials and encourages research into this paradigm for understanding how best to close the gaps between knowledge and effective practice. The five-year goals are to enhance the capacity of Canadian investigators to lead major clinical studies, facilitate knowledge translation and exchange, and augment Canada{\textquoteright}s capacity to train the next generation of leaders in cardiovascular and diabetes clinical research.",
year = "2010",
doi = "10.1016/S0828-282X(10)70408-6",
language = "English",
volume = "26",
pages = "353--358",
journal = "Canadian Journal of Cardiology",
issn = "0828-282X",
publisher = "Pulsus Group Inc.",
number = "7",
}
